Arcturus Therapeutics Holdings (ARCT) Payables (2018 - 2026)

Arcturus Therapeutics Holdings' Payables history runs 9 years deep, the most recent figure standing at $4.1 million for Q1 2026.

• Quarterly Payables fell 33.76% year-over-year to $4.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.1 million (down 33.76% YoY) and the FY2025 annual result came in at $4.2 million, down 41.13% from the prior year.
• Payables was $4.1 million for Q1 2026 at Arcturus Therapeutics Holdings, down from $4.2 million in the prior quarter.
• Across five years, Payables topped out at $19.3 million in Q1 2023 and bottomed at $4.1 million in Q1 2026.
• A 5-year average of $9.9 million and a median of $9.1 million in 2024 frame the typical range for Payables.
• Annual changes were most pronounced in 2023 — Payables jumped 136.36% — and 2024, when it plunged 52.73%.
• Arcturus Therapeutics Holdings' Payables stood at $7.4 million in 2022, then retreated by 29.13% to $5.3 million in 2023, then jumped by 36.28% to $7.2 million in 2024, then slumped by 41.13% to $4.2 million in 2025, then decreased by 3.35% to $4.1 million in 2026.
• Business Quant data shows ARCT's Payables at $4.1 million in Q1 2026, $4.2 million in Q4 2025, and $5.5 million in Q3 2025.